India, Aug. 13 -- Editas Medicine, Inc. (EDIT) jumped 35.15 percent to $3.09, rising $0.80 on Wednesday, after Custom Market Insights released a report projecting strong growth in the synthetic biology market.
The stock opened at $2.45 and traded between $2.44 and $3.10, with 4.68 million shares changing hands compared to an average of 2.46 million on the Nasdaq. Editas Medicine's 52-week range is $0.91 to $4.19.
Industry experts highlighted increasing demand for sustainable solutions such as biofuels, biodegradable plastics, and eco-friendly chemicals, alongside advances in gene editing and biotechnology that could drive innovation in healthcare, agriculture, and industrial applications.
For comments and feedback contact: editorial@rttn...